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LevetiracetamWe assessed the clinical characteristics and efﬁcacy of neurotransmitters and levetiracetam in a patient with
hyperphenylalaninemia due to dihydropteridine reductase (DHPR) deﬁciency who developed epileptic seizures.
A boywith DHPR deﬁciency,whohad been successfully treatedwith tetrahydrobiopterin (BH4), levodopa, and 5-
hydroxytryptophan (5-HTP) since he was 2 months old, started having monthly episodes of blurred vision, loss
of consciousness, and falls at the age of 12 years. He was taking BH4 510 mg/day, levodopa 670 mg/day, 5-HTP
670 mg/day, and entacapone 300 mg/day. We evaluated the seizure semiology, EEG ﬁndings, and efﬁcacy of
levodopa, 5-HTP, and levetiracetam (LEV). His seizures were comprised of an abrupt loss of awareness and eye
deviation to the right. Interictal EEG showed slightly slow posterior-dominant rhythm in 7–8 Hz; intermittent,
irregular slowing in the bilateral parieto-occipital region; and multiregional independent spikes in bilateral
hemispheres. Ictal EEG showed a seizure pattern starting at the left temporal region. Brain MRI showed diffuse
signal increase of deep white matter on T2-weighted and FLAIR images. Dosage increase of levodopa to
1340 mg/day, of 5-HTP to 1500 mg/day, or of both did not suppress seizures. Levetiracetam 2000 mg/daymark-
edly reduced seizures without any adverse events. Patients with DHPR deﬁciency can develop epileptic seizures
of partial onset which can be successfully and safely treated with LEV.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Dihydropteridine reductase (DHPR) deﬁciency is a rare inherited
disorder which affects the metabolism of tetrahydrobiopterin (BH4),
causing hyperphenylalaninemia and neurotransmitter deﬁciency [1].
In Japan, about 1 per 2 million newborns is diagnosed with BH4 deﬁ-
ciency, and about 10% of them have DHPR deﬁciency [2]. In an interna-
tional survey, DHPR deﬁciency is the secondmost common form of BH4
deﬁciency (34.7%) [3]. Dihydropteridine reductase deﬁciency in pa-
tients is highly associated with epileptic seizures that are frequently
severe [3,4]. However, the clinical characteristics of their seizures, EEG
ﬁndings, and treatment strategies have not been fully established.
Here, we assessed the clinical characteristics and efﬁcacy of neuro-
transmitters and levetiracetam (LEV) to epileptic seizures in a patient
with DHPR deﬁciency who had been successfully treated with BH4,
levodopa, and 5-hydroxytryptophan (5-HTP). Part of this manuscriptcs, Okayama Medical Center,
u, Okayama 701-1192, Japan.
ujo).
. This is an open access article underwas presented at the 30th International Epilepsy Congress, 2013, and
appeared in an abstract form [5].
2. Case presentation
A boy, the second child of nonconsanguineous parents, was born at
38 weeks of gestation with a weight of 3.1 kg. At 4 days, phototherapy
was done for jaundice. He was found to have hyperphenylalaninemia
on a routine Guthrie test for newborn screening. His older brother is
healthy. His serum phenylalanine (Phe) level ranged between 492 and
756 μmol/l (normal range: 38–91 μmol/l [4]). He was diagnosed as
having DHPR deﬁciency based on a BH4 loading test; the measurement
of urinary, serum, and CSF pterins; the DHPR activity in dried blood
spots; and the presence of neurotransmitter metabolites in the urine
and CSF. Details of these diagnostic tests were described in our previous
paper [6]. Gene analysis revealed a compound heterozygous muta-
tion of the QDPR gene (G18C/S59X, both are new mutations). At
2 months, treatment was started with BH4 15–20 mg/kg/day, levodopa
15 mg/kg/day, and 5-HTP 15 mg/kg/day, as previously described [4].
The dosage of BH4 was adjusted to keep his serum Phe concentration
less than 480 μmol/l without dietary restriction of Phe [6]. Entacapone
300 mg/day was added at the age of 10 years. With this therapy, histhe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. Interictal EEG. (a) Slightly slow posterior dominant rhythm in 7–8Hz and intermittent irregular slowwaves in the bilateral parieto-occipital regions. (b)Multiregional independent
spikes in bilateral hemispheres.
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istered because its level in his serum – 3.4–5.9 ng/ml (normal range:
3.6–12.9 ng/ml) – is of sufﬁcient amount. He attended an ordinary
elementary school, though he showed mild mental retardation (IQ of
around 60).P3-O2
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Fig. 2. Ictal EEG. An electroencephalographic seizure pattern starting at the left temporal region
was conscious in this particular event, but the same pattern of EEG was observed while he exhHowever, he started having monthly episodes of blurred vision, loss
of consciousness, and falls at the age of 12 years. At that time, he was
taking BH4 510 mg/day, levodopa 670 mg/day, 5-HTP 670 mg/day,
and entacapone 300 mg/day. Interictal EEG showed slightly slow poste-
rior-dominant rhythm in 7–8 Hz; intermittent irregular slow waves inpread to R temporal region The patient said ‘nothing wrong’
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and then a rhythmic burst of fast activities starting at the right temporal region. The patient
ibited consciousness disturbance in other complex partial seizures.
RFig. 3. Brain MRI, FLAIR images at the age of 12 years. Note diffuse signal increase of deep white matter.
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spikes in bilateral hemispheres (Fig. 1). During EEG recordings, he had
habitual seizures which comprised an abrupt loss of awareness and
eye deviation to the right without convulsion. Ictal EEG showed an
electrographic seizure pattern starting at the left temporal region and
then a burst of fast activities spreading to the other side (Fig. 2). Brain
MRI showed diffuse signal increase of deep white matter on T2-
weighted and FLAIR images (Fig. 3). Dosage increase of levodopa to
1340 mg/day, of 5-HTP to 1500 mg/day, or of both did not suppress
his seizures. Levetiracetam 2000 mg/day markedly reduced seizures
without any adverse events.
3. Discussion
The presentmale patientwith DHPR deﬁciency, whohad been treat-
ed with supplementation of neurotransmitters since he was 2 months
old, developed epileptic seizures at the age of 12 years. By EEG evalua-
tion of ictal and interictal epochs, we could document that his epileptic
seizures were complex partial seizures originating from the left tempo-
ral region, and he also has diffuse and multiregional abnormalities.
We also demonstrated that antiepileptic drugs such as LEV should be
introduced in order to suppress his seizures; on the other hand, dosage
increase of neurotransmitter supplementation was not effective.
A previous paper described that 6 out of 10 patients with DHPR
deﬁciency,whose onset of neurotransmitter treatmentwas at 6 months
of age or older, developed severe epileptic seizures [4]. The present case,
where the treatment was started when the patient was 2 months old,
suggests that neurotransmitter supplementation should be started
earlier than 2 months to prevent the development of seizures. In litera-
ture describing severe seizures or convulsions in patients with DHPR
deﬁciency, seizure types are myoclonic seizures [7] and seemingly gen-
eralized tonic–clonic seizures, considering that their EEG showed gener-
alized hypsarrhythmic activity or diffuse sharp wave activity [4,8,9]. In
contrast, our patient showed complex partial seizures. This may also
suggest that the timing of treatment administration may affect the
clinical seizure types.
Phenobarbital, clonazepam, and sodium valproate (VPA) have been
used to treat severe seizures in patients with DHPR deﬁciency [4,8,9].
However, antiepileptic drugs can lead to adverse events; VPA, in par-
ticular, may lead to extrapyramidal tract signs that can worsen
the symptoms in patients with DHPR deﬁciency and in patientswith other metabolic disorders with dopamine depletion. Our experi-
ence with this patient suggests that LEV can be used in DHPR deﬁciency
safely.
4. Conclusion
Patients with DHPR deﬁciency can develop epileptic seizures of
partial onset, which can be successfully and safely treatedwith LEV. Fur-
ther studies are needed to clarify themechanism of epileptogenesis and
the therapeutic strategies in patients with DHPR deﬁciency.
Conﬂict of interest
The authors declare that they have no conﬂict of interets.
Acknowledgment
This study was supported in part by Health and Labour Sciences
Research Grants for Research on Rare and Intractable Diseases.
References
[1] Shintaku H. Disorders of tetrahydrobiopterin metabolism and their treatment. Curr
Drug Metab 2002;3:123–31.
[2] Shintaku H, Ohwada M. Long-term follow-up of tetrahydrobiopterin therapy in
patients with tetrahydrobiopterin deﬁciency in Japan. Brain Dev 2013;35:406–10.
[3] Opladen T, Hoffmann GF, Blau N. An international survey of patients with
tetrahydrobiopterin deﬁciencies presenting with hyperphenylalaninaemia.
J Inherit Metab Dis 2012;35:963–73.
[4] Jäggi L, Zurﬂüh MR, Schuler A, Ponzone A, Porta F, Fiori L, et al. Outcome and long-
term follow-up of 36 patients with tetrahydrobiopterin deﬁciency. Mol Genet
Metab 2008;93:295–305.
[5] FurujoM, Kinoshita M, Shintaku H, Kubo T. Clinical characteristics of epileptic seizures
in a case of dihydropteridine reductase deﬁciency. Epilepsia 2013;54(s3):234.
[6] FurujoM, Ichiba Y, Sintaku H, AsadaM. A case of dihydropteridine reductase deﬁciency.
Pteridines 2000;11:126–8.
[7] Cotton RG, Jennings I, Bracco G, Ponzone A, Guardamagna O. Tetrahydrobiopterin
non-responsiveness in dihydropteridine reductase deﬁciency is associated with the
presence of mutant protein. J Inherit Metab Dis 1986;9:239–43.
[8] Longhi R, Valsasina R, Buttè C, Paccanelli S, Riva E, Giovannini M. Cranial computer-
ized tomography in dihydropteridine reductase deﬁciency. J Inherit Metab Dis
1985;8:109–12.
[9] Longhi R, Riva E, Valsasina R, Paccanelli S, Giovannini M. Phenylketonuria due to
dihydropteridine reductase deﬁciency: presentation of two cases. J Inherit Metab
Dis 1985;8(s2):97–8.
